<?xml version="1.0" encoding="UTF-8"?>
<p>Many efforts have been directed to develop vaccines against human CoV infections in recent decades, but a limiting factor is the degree of cross-protection rendered by these vaccines due to their extensive sequence diversity.
 <sup>
  <xref rid="CIT0005">5</xref>
 </sup> Various vaccines, immunotherapeutics, and drug options have been explored during the recent threats of Zika, Ebola, and Nipah viruses
 <sup>
  <xref rid="CIT0006">6</xref>-
  <xref rid="CIT0008">8</xref>
 </sup> as well as against previous CoVs including SARS- and MERS-CoVs.
 <sup>
  <xref rid="CIT0003">3</xref>,
  <xref rid="CIT0005">5</xref>,
  <xref rid="CIT0009">9</xref>-
  <xref rid="CIT0012">12</xref>
 </sup> These valuable options can be exploited for their potency, efficacy, and safety along with expediting other ongoing research
 <sup>
  <xref rid="CIT0002">2</xref>,
  <xref rid="CIT0004">4</xref>,
  <xref rid="CIT0013">13</xref>-
  <xref rid="CIT0015">15</xref>
 </sup> so as to discover valuable modalities for tackling the emerging COVID-19, but as yet there is no effective vaccine or therapeutic, for which intense efforts are ongoing.
</p>
